After twenty years of investment in research, tuberculosis (TB) vaccine development has strengthened, with sixteen candidates with the potential to help reach the global TB elimination target in 2030.
Announced today, Wellcome and the Bill & Melinda Gates Foundation are funding $550 million to advance the TB vaccine candidate M72/AS01E (M72) through a Phase III clinical trial.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
